Influenza B virus conserved epitopes (IBV conserved epitopes)

Influenza B virus conserved epitopes are stable antigenic sites located on viral proteins such as the hemagglutinin (HA) stalk, neuraminidase (NA), and nucleoprotein (NP) that show minimal variation across the Victoria and Yamagata lineages (Dreyfus et al., 2012, Science). These epitopes are the primary focus for universal influenza vaccine strategies, as they offer the potential for broad-spectrum immunity that bypasses the need for annual strain-specific updates (Krammer, 2020, Nature). Broadly neutralizing antibodies, such as CR9114, target the HA stalk to prevent the pH-triggered conformational changes necessary for viral-host membrane fusion (Dreyfus et al., 2012, Science). Additionally, conserved regions in the NA protein are targeted to inhibit the enzymatic cleavage of sialic acid, thereby preventing the release of progeny virions (Wohlbold et al., 2015, Journal of Virology). While these epitopes are less immunodominant than the HA head, their stability makes them ideal for eliciting long-lived, cross-reactive immune responses (Tan et al., 2016, Journal of Virology). Therapeutic development focusing on these targets aims to reduce the global burden of seasonal influenza and provide a safeguard against emerging viral variants.

Other names

Influenza B conserved regionsIBV HA stalk epitopesInfluenza B universal vaccine targetsConserved IBV antigens

Neutralization of viral entry by binding to the conserved stem region of hemagglutinin, inhibition of neuraminidase activity, and induction of Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) (Dreyfus et al., 2012, Science; Wohlbold et al., 2015, Journal of Virology).